Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2010
09/30/2010US20100249038 Antagonists of the receptor for advanced glycation end-products (rage)
09/30/2010US20100249030 Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
09/30/2010US20100249029 Peptides with high affinity for the prolactin receptor
09/30/2010US20100249025 Peptide antagonists of vascular endothelial growth factor
09/30/2010US20100249023 Isoflavone formulation
09/30/2010US20100249022 Strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
09/30/2010US20100249019 Use of a peptide as a therapeutic agent
09/30/2010US20100249017 Use of cnp-22, alone or in combination with physalemin, as a therapeutic agent
09/30/2010US20100248241 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
09/30/2010US20100248240 Gene and protein relating to hepatocellular carcinoma and methods of use thereof
09/30/2010US20100247691 Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products
09/30/2010US20100247683 Methods of identifying potential components for targeted drug delivery compositions
09/30/2010US20100247675 Magnotherapy products
09/30/2010US20100247674 Magnotherapy products
09/30/2010US20100247668 Polymer-agent conjugates, particles, compositions, and related methods of use
09/30/2010US20100247662 Biologic Modulations with Nanoparticles
09/30/2010US20100247657 Telomerase reverse transcriptase variant
09/30/2010US20100247643 Oral formulations
09/30/2010US20100247640 Solid Oral Dosage Form Containing An Enhancer
09/30/2010US20100247623 Cancer Stem Cell Vaccine
09/30/2010US20100247622 Treatment regime for proliferative disorders
09/30/2010US20100247620 Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product
09/30/2010US20100247607 Implantable formulations of bisphosphonic acids
09/30/2010US20100247580 Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
09/30/2010US20100247579 Therapeutic agent for cancer
09/30/2010US20100247562 Complexes Derived from Heterohybrid Cells and Uses Thereof
09/30/2010US20100247556 Method for activation of helper t cell and composition for use in the method
09/30/2010US20100247553 Goodpasture Antigen Binding Protein
09/30/2010US20100247545 Antibodies to m-csf
09/30/2010US20100247544 Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms
09/30/2010US20100247542 Truncated variant of the mammalian target for rapamycin (mtor) protein
09/30/2010US20100247541 novel antigen associated with the neovasculature of tumour metastases
09/30/2010US20100247539 Antibodies that Inhibit Transport Activity of Peptide Transporters
09/30/2010US20100247536 Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
09/30/2010US20100247533 TREATMENT WITH A HUMANIZED ANTI-EGFR IgG1 ANTIBODY AND IRINOTECAN
09/30/2010US20100247531 Anti-fgfr3 antibodies and methods using same
09/30/2010US20100247528 Arrays, kits and cancer characterization methods
09/30/2010US20100247526 Anti-NKG2A Antibodies and Uses Thereof
09/30/2010US20100247523 Subtypes of humanized antibody against interleuken-6 receptor
09/30/2010US20100247520 Mutated netrin 4, fragments thereof and uses thereof as drugs
09/30/2010US20100247518 Modified proteins, designer toxins, and methods of making thereof
09/30/2010US20100247516 Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
09/30/2010US20100247515 Polypeptides, antibody variable domains and antagonists
09/30/2010US20100247508 Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
09/30/2010US20100247506 Formation of stable submicron peptide or protein particles by thin film freezing
09/30/2010US20100247502 Tumor/b-cell hybrid cells and uses thereof
09/30/2010US20100247492 Methods for the detection of circulating tumor cells
09/30/2010US20100247488 Paramyxoviridae Virus Preparations
09/30/2010US20100247484 Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
09/30/2010US20100247482 Tight junction modulator peptides for enhanced mucosal delivery of therapeutic compounds
09/30/2010US20100247468 Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds
09/30/2010US20100247462 Synthesis of resveratrol-based natural products
09/30/2010US20100247447 Drug delivery system for hydrophobic drugs
09/30/2010US20100247445 Polymeric drug carrier for image-guided delivery
09/30/2010US20100247440 Mycobacterial immunotherapy for cancer treatment
09/30/2010US20100247439 Dendritic nano-antioxidants
09/30/2010US20100247436 In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
09/30/2010US20100247434 Anti-Angiogenic Extracts from Pomegranate
09/30/2010US20100247432 Marker for the diagnosis of cancer
09/30/2010US20100247427 Methods of inhibiting cell growth and methods of enhancing radiation responses
09/30/2010DE102009014484A1 Substituierte Piperidine Substituted piperidines
09/30/2010CA2756851A1 Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug
09/30/2010CA2756789A1 Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
09/30/2010CA2756594A1 Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
09/30/2010CA2756566A1 Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
09/30/2010CA2756452A1 Methods and compositions for the treatment of cancer
09/30/2010CA2756347A1 Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
09/30/2010CA2756099A1 Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
09/30/2010CA2756067A1 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
09/30/2010CA2755983A1 Compounds and methods for modulating an immune response
09/30/2010CA2754416A1 Novel medicament for treating cognitive impairment
09/30/2010CA2753988A1 Novel anti-.alpha.5.beta.1 antibodies and uses thereof
09/29/2010EP2233571A1 Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same
09/29/2010EP2233561A1 Method for amplification of hematopoietic stem cell using heterocyclic compound
09/29/2010EP2233501A1 Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof
09/29/2010EP2233486A1 Azaindoles
09/29/2010EP2233483A1 Indole or Benzimidazole derivatives as IkB-kinase modulators and intermediates in their preparation.
09/29/2010EP2233467A1 Alpha-amino-n-substituted amides, pharmaceutical composition containing them and uses thereof
09/29/2010EP2233463A1 New compounds isolated from extract of antrodia camphorata
09/29/2010EP2233156A2 Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
09/29/2010EP2233148A1 Uses of pdcd5 polypeptide for tumor chemotherapy and organ protection
09/29/2010EP2233135A1 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
09/29/2010EP2231707A1 Anti mif antibodies
09/29/2010EP2231695A1 Antitumoral compounds
09/29/2010EP2231684A1 Compounds and methods for the treatment of cancer
09/29/2010EP2231664A1 4-(pyrroloý2,3-c¨pyridine-3-yl)-pyrimidine-2-amine derivatives
09/29/2010EP2231662A1 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents
09/29/2010EP2231661A1 Inhibitors of pi3 kinase
09/29/2010EP2231659A1 Translocator protein ligands
09/29/2010EP2231656A1 Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
09/29/2010EP2231654A1 Novel 2-substituted thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
09/29/2010EP2231652A1 Novel 2-hetaryl thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
09/29/2010EP2231649A1 Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
09/29/2010EP2231641A2 Quinoxaline and quinoline derivatives as kinase inhibitors
09/29/2010EP2231638A1 Phthalazinone derivatives
09/29/2010EP2231637A1 Pyridazine fungicides
09/29/2010EP2231636A1 Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
09/29/2010EP2231625A1 Thiazole and oxazole kinase inhibitors
09/29/2010EP2231623A1 5-phenyl-lh-benz0 [e] [1, 4] diazepine compounds substituted with an hydroxamic acid group as histone deacetylase inhibitors
09/29/2010EP2231620A1 Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
1 ... 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 ... 2211